Abstract Number: 0262 • ACR Convergence 2026
Data-Driven Glucocorticoid Exposure Trajectories and Predictors of High-Dose Use in Lupus Nephritis
Background/Purpose: Although glucocorticoids (GCs) are widely used in lupus nephritis (LN), patterns of real-world GC exposure during LN treatment remain poorly characterized. We aimed to…Abstract Number: 0332 • ACR Convergence 2026
Prospective Risk Stratification for Lupus Nephritis in Systemic Lupus Erythematosus: Retrospective Validation of a Multi-Layer Computational Engine
Background/Purpose: Lupus nephritis (LN) is a major cause of renal morbidity in Systemic Lupus Erythematosus (SLE) patients. To address the clinical need for earlier and…Abstract Number: 1021 • ACR Convergence 2026
Machine Learning-Based Automated Assessment of the Prognostic Utility of Glomerular Tuft Pathomics in Lupus Nephritis
Background/Purpose: Patients with LN are treated with diverse immunosuppressive therapies; however, only a subset achieves a complete response. Earlier identification of patients likely to be…Abstract Number: 1235 • ACR Convergence 2026
Outcomes of Pure Membranous Lupus Nephritis at a South Indian Tertiary Referral center: A Retrospective Cohort Study
Background/Purpose: Pure membranous lupus nephritis (PMLN) is a distinct lupus nephritis subtype with limited data on remission kinetics and predictors of response, particularly from South…Abstract Number: 1298 • ACR Convergence 2026
Urinary Complement Activation Products and Soluble CD163 as Lupus Nephritis Biomarkers
Background/Purpose: The gold standard for diagnosing lupus nephritis (LN) is renal biopsy, an invasive procedure with associated risks. While traditional biomarkers such as proteinuria and…Abstract Number: 1984 • ACR Convergence 2026
Defining the Molecular Landscape of Lupus Nephritis by Comparative Transcriptomic Profiling
Background/Purpose: Heterogeneity among lupus nephritis (LN) patients hinders assessment of the immune drivers of disease progression and the assignment of the most appropriate therapeutic agents.…Abstract Number: 2259 • ACR Convergence 2026
Lupus Nephritis Still Imposes High Rates of Renal Replacement Therapy and Mortality in Young Individuals. Long-term Analysis in 330 Real-life Patients
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), with significant risk of end-stage renal disease (ESRD) and increased mortality. Previous…Abstract Number: 2833 • ACR Convergence 2026
Single cell annotation with B-CellAnnoTator reveals plasma cell subsets associated with clinical outcome in lupus nephritis
Background/Purpose: B cells play a fundamental role in immune-mediated disease (IMD) pathogenesis; this was recently demonstrated by the unprecedented drug free remissions yielded by deep…Abstract Number: 0265 • ACR Convergence 2026
Dual CD19/BCMA Targeting CAR-T therapy Induces Deeper B-Cell Eradication, Complete Immune Reset, and Superior Remission Outcomes Compared to Single-Target CD19 CAR-T Therapy in Systemic Lupus Erythematosus and Lupus Nephritis
Background/Purpose: Durable remission in autoantibody (Ab)-driven diseases require eradication of both autoreactive B cells and long-lived plasma cells (LLPCs) for "full" immune reset. CD19-directed CAR-Ts…Abstract Number: 0334 • ACR Convergence 2026
Renal Histopathological Patterns in Lupus Nephritis: A Single-Center Cohort Study.
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity in systemic lupus erythematosus (SLE) and a leading cause of end-stage kidney disease. Data describing…Abstract Number: 1065 • ACR Convergence 2026
Smoldering Neutrophil-Mediated Inflammation in pSLE: Persistent NETs Despite Standard Therapy
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a severe autoimmune disease with earlier onset and greater organ involvement, with lupus nephritis (pLN) developing in up…Abstract Number: 1236 • ACR Convergence 2026
Preliminary Efficacy and Safety Results of Equecabtagene Autoleucel in Severe Refractory Lupus Nephritis, with a Case of Concomitant Psoriasis and Sjögren’s Syndrome
Background/Purpose: SLE is a complex autoimmune disease characterized by persistent B cell hyperactivation, autoantibody production, and heightened autoreactivity against self-antigens. Equecabtagene Autoleucel, a fully human…Abstract Number: 1725 • ACR Convergence 2026
Lifetime Societal Burden of Systemic Lupus Erythematosus (SLE): Economic and Humanistic Insights from a U.S. State-Transition Modeling Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disease associated with significant morbidity, premature mortality, and reduced quality of life. Lupus nephritis (LN), which develops in…Abstract Number: 1988 • ACR Convergence 2026
Extracellular Vesicles as Potential Biomarkers for Disease Activity and Monitoring in Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) affects 40-60% of patients with systemic lupus erythematosus (SLE) and requires early and accurate diagnosis to prevent damage and enable appropriate…Abstract Number: 2263 • ACR Convergence 2026
Patient Experiences with Home Urine Protein Testing in Patients at High Risk of Lupus Nephritis: A Qualitative Study
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). Proteinuria is a critical biomarker for renal involvement, but early or transient…
ACR Meeting Abstracts